Agenda
Cancer Progress 2011
March 8-9, 2011
The Westin New York at Times Square

Tuesday, March 8

8:15-8:30         Opening Remarks, Jeremy Goldberg

8:30-9:45          Novel strategies for drug development in oncology
Moderator: Jamie Freedman, MD, PhD, Vice President, Cancer Research, Oncology, GlaxoSmithKline
Christopher Slapak, MD, Distinguished Lilly Scholar - Oncology Business Unit - Exploratory/Pre-Clinical, Eli Lilly
Colin Hill, CEO, GNS Healthcare
Catherine Wheeler, MD, Site Head, Translational Medicine, Oncology, Roche
H. Kim Lyerly, MD, Director, Duke Comprehensive Cancer Center , George Barth Geller Professor of Cancer Research, Duke University
Tal Zaks, MD, PhD, Vice President Oncology Clinical Development, Sanofi-Aventis

9:45-10:45        Keynote Discussion: Health Technology Assessment and Comparative Effectiveness Impact in Oncology 
Moderator: Jeremy Goldberg
Sir Michael Rawlins, MD, Chairman NICE
Scott Gottlieb, MD, Resident Fellow, American Enterprise Institute for Public Policy Research 

10:45-11:15      Networking Break


11:15-11:45      "Prioritization of Immunotherapy Agents & Vaccines That Could Cure Cancers"
Martin A. “Mac” Cheever MD, Member & Director of Solid Tumor Research, Fred Hutchinson Cancer Research Center , Professor of Medicine/Oncology, University of Washington

11:45-12:45      Immuno-Oncology
Moderator: Dendritic Vaccines – David Urdal, PhD, SVP, CSO, Dendreon
Martin A. “Mac” Cheever MD, Member & Director of Solid Tumor Research, Fred Hutchinson Cancer Research Center
MUC1 – Robert Kirkman, MD, President & CEO, Oncothyreon
Multi-Targets – Thomas Davis, MD, Senior Vice President and Chief Medical Officer,  Celldex  
The Role of Regulatory T Cells in Cancer – Theresa Whiteside, PhD, Professor of Pathology and Immunology, University of Pittsburgh , School of Medicine

12:45-2:00        Luncheon

2:00-3:00          New Targets Session 1 -An Update on PI3K, MEK, mTOR
Moderator: Neal Rosen, MD, PhD, Enid A. Haupt Chair in Medical Oncology, Member, MSKCC  - (Feedback)
Levi Garraway, MD, PhD, Associate Member, The Broad Institute (Melanoma)
Lewis Cantley, PhD, Professor of Systems Biology, Chief, Division of Signal Transduction, Department of Medicine, Beth Israel Deaconess Medical Center

3:00-3:30          New Developments in Prostate Cancer: Androgen Receptor Axis – Scientific and Clinical Implications and an Update on Prostate Cancer Drugs in Development
Howard I. Scher, MD, Chief, Genitourinary Oncology Service; D. Wayne Calloway Chair in Urologic Oncology, Memorial Sloan-Kettering Cancer Center

3:30-5:00         New Targets Session  2
Moderator: Ivor Royston , MD , Managing Member, Forward Ventures
BRAF inhibitors –Keith T. Flaherty, MD, Director, Developmental Therapeutics, Massachusetts General Hospital
T-DM1 Breast Cancer –  Ellie Guardino, MD, PhD, Medical Director, T-DM1, Genentech
CYP17 – Prostate cancer,  Michael Meyers, MD, VP Hematology/Oncology Compound Development, J&J
PARP – Daniel Silver, MD, PhD, Assistant Professor of Medical Oncology/Cancer Biology, Dana Farber Cancer Institute
Stem Cells – Robert Forrester, COO, Verastem
Targeting metabolism – Scott Biller, PhD, CSO, Agios Pharmaceuticals 

5:00-6:30          Reception

Wednesday, March 9

8:00-8:15          Opening Remarks – Mark Simon

8:15-8:45         Adaptive Clinical Trials in Oncology: A Necessary Step
Donald Berry, PhD, Head, Division of Quantitative Sciences & Chairman, Department of Biostatistics  & Frank T. McGraw Memorial Chair of Cancer Research, The University of Texas M.D. Anderson Cancer Center

8:45-10:15        Diagnostics –
Moderator: Steve Averbuch, MD, VP, Oncology Transition Strat/Dev, Head Pharmacodiagnostics, Bristol-Myers Squibb
Challenges of Simultaneous Drug-Diagnostic Development – Richard Buller, MD, PhD, VP Translational Medicine, Oncology, Pfizer
Challenges for Personalized Medicine– J. Carl Barrett, PhD, Vice President and Global Head, Oncology Biomarkers and Imaging, Oncology Translational Medicine, Oncology Business Unit,
Novartis Institutes of BioMedical Sciences, Inc. Novartis
Colorectal Cancer - Graham Lidgard, PhD, CSO, Exact Sciences
Farideh Bischoff, PhD, Director, Clinical Development, BioCept
Brian Leyland-Jones, MD, PhD, Emory University

10:10-10:45      Special Presentation: Antibody Conjugates for Cancer Therapy
Robert Abraham, PhD, Senior Vice President and Chief Scientific Officer, Oncology Research Unit, Pfizer Worldwide Research and Development, Pfizer R&D

10:45-11:15      Networking Break

11:15-12:15      What to do if your drug falls into a stratified segment
Moderator: Colin Bier, PhD, Managing Director, ABA BioResearch
Christopher Bowden, MD, Vice President Product Development, Clinical Oncology, Genentech
Gary Kelloff, MD, Advisor, DCTD, CIP, National Cancer Institute

12:15-12:45      Oncology Market Overview: Barriers, Challenges and Value
Bill Bagwell, RPh, Senior Vice President, Clinical and Scientific Assessment, Kantar Health
Rhoda Dunn, Account Director, Market Access, Kantar Health

12:45-2:00        Luncheon
 

2:00 – 2:30        Rapid Approval of New Medicines and Combos in Oncology
Moderator, Mark Simon, Williver Group
Nancy Simonian, MD, CMO, Clinical, Regulatory and Medical Affairs, Millennium,The Takeda Oncology Company
Jamey Skillings, MD, MSc, Vice President, Medical Affairs, Pfizer

2:30-3:00        Synthetic Lethality As A Strategy To Improve Molecularly Targeted Therapy
Erica Golemis, PhD, Professor, Deputy Chief Scientific Officer & Vice President, Co-Leader, Developmental Therapeutics, Co-Leader, Head and Neck Cancer Keystone, Director, High Throughput Screening and Translational Research Facility, Fox Chase Cancer Center

3:00 Conference Concludes 

Slides (attendees only)        Description               Sponsors